Intraarterial sodium nitroprusside infusion in the treatment of severe ergotism.
Treatment of migraine with ergot alkaloids may produce systemic vasospasm in patients, especially as a result of automedication and overconsumption but also due to individual hypersensitivity. Peripheral vasoconstriction may lead to gangrene of the extremities, necessitating amputation. Various treatments have been tried against ischemic complications during ergotism with varied and unpredictable results. We report two recent cases of severe acute peripheral ischemia due to ergotamine abuse successfully treated with continuous systemic sodium nitroprusside infusion. The doses used during intraarterial injection are well below those known to be toxic. Consequently, the adverse effects of cyanide toxicity can be avoided. We think that intraarterial infusion of sodium nitroprusside, associated with forced diuresis and the administration of hydroxycobalamin, constitutes the treatment of choice of extreme peripheral ischemia of ergotism.
D000328:Adult; D002110:Caffeine / Q000009:adverse effects / Q000037:antagonists & inhibitors; D004338:Drug Combinations / Q000009:adverse effects / Q000037:antagonists & inhibitors; D004878:Ergotamine / Q000009:adverse effects / Q000037:antagonists & inhibitors; D004881:Ergotism / Q000188:drug therapy*; D005260:Female; D005292:Ferricyanides / Q000627:therapeutic use*; D006801:Humans; D007261:Infusions, Intra-Arterial; D009599:Nitroprusside / Q000008:administration & dosage / Q000627:therapeutic use*
D004338:Drug Combinations; D005292:Ferricyanides; C037330:caffeine, ergotamine drug combination; D009599:Nitroprusside; D002110:Caffeine; D004878:Ergotamine